{"url_path":"/sec/bysi/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1677940/0001171843-26-003372-index.html","accession_number":"0001171843-26-003372","cik":"0001677940","ticker":"BYSI","issuer_name":"BeyondSpring Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1677940/0001171843-26-003372-index.html","primary_entity_key":"0001677940","primary_entity_name":"BeyondSpring Inc."},"word_count":1807,"has_tables":true,"body_markdown":"bysi20260331_10q.htm\n\nQ1\n2026\n--12-31\nfalse\n0001677940\nfalse\nfalse\nfalse\nfalse\n5\n4\n0\n0\n\n00016779402026-01-012026-03-31\nthunderdome:item\niso4217:USD\n00016779402026-03-31\n00016779402025-12-31\n0001677940country:US2026-03-31\n0001677940country:US2025-12-31\n0001677940country:CN2026-03-31\n0001677940country:CN2025-12-31\n00016779402025-01-012025-03-31\nxbrli:pure\n0001677940srt:MaximumMemberbysi:SeedMember2024-12-13\n0001677940srt:MinimumMemberbysi:SeedMember2024-12-13\n0001677940bysi:SEEDTherapeuticsIncMember2020-11-122020-11-12\niso4217:USDxbrli:shares\n0001677940bysi:SEEDTherapeuticsIncMember2020-11-12\n0001677940us-gaap:PensionPlansDefinedBenefitMember2026-01-012026-03-31\n0001677940us-gaap:PensionPlansDefinedBenefitMember2025-01-012025-03-31\n0001677940bysi:Seed2022ShareIncentivePlanMember2026-01-012026-03-31\n0001677940bysi:Seed2022ShareIncentivePlanMember2025-01-012025-03-31\n0001677940bysi:GeneralAndAdministrativeExpensesMemberbysi:Seed2022ShareIncentivePlanMember2026-01-012026-03-31\n0001677940bysi:GeneralAndAdministrativeExpensesMemberbysi:Seed2022ShareIncentivePlanMember2025-01-012025-03-31\n0001677940bysi:ResearchAndDevelopmentExpensesMemberbysi:Seed2022ShareIncentivePlanMember2026-01-012026-03-31\n0001677940bysi:ResearchAndDevelopmentExpensesMemberbysi:Seed2022ShareIncentivePlanMember2025-01-012025-03-31\nxbrli:shares\nutr:Y\n0001677940bysi:Seed2022ShareIncentivePlanMembersrt:MaximumMember2026-01-012026-03-31\n0001677940bysi:Seed2022ShareIncentivePlanMembersrt:MinimumMember2026-01-012026-03-31\n0001677940bysi:The2017OmnibusIncentivePlanMember2026-01-012026-03-31\n0001677940bysi:The2017OmnibusIncentivePlanMember2025-01-012025-03-31\n0001677940bysi:GeneralAndAdministrativeExpensesMemberbysi:The2017OmnibusIncentivePlanMember2026-01-012026-03-31\n0001677940bysi:GeneralAndAdministrativeExpensesMemberbysi:The2017OmnibusIncentivePlanMember2025-01-012025-03-31\n0001677940bysi:ResearchAndDevelopmentExpensesMemberbysi:The2017OmnibusIncentivePlanMember2026-01-012026-03-31\n0001677940bysi:ResearchAndDevelopmentExpensesMemberbysi:The2017OmnibusIncentivePlanMember2025-01-012025-03-31\n0001677940bysi:The2017OmnibusIncentivePlanMember2017-03-09\n0001677940us-gaap:SegmentContinuingOperationsMember2026-01-012026-03-31\n0001677940us-gaap:SegmentContinuingOperationsMember2025-01-012025-03-31\n0001677940us-gaap:LeaseholdImprovementsMember2026-03-31\n0001677940us-gaap:LeaseholdImprovementsMember2025-12-31\n0001677940us-gaap:AutomobilesMember2026-03-31\n0001677940us-gaap:AutomobilesMember2025-12-31\n0001677940bysi:LaboratoryEquipmentMember2026-03-31\n0001677940bysi:LaboratoryEquipmentMember2025-12-31\n0001677940us-gaap:OfficeEquipmentMember2026-03-31\n0001677940us-gaap:OfficeEquipmentMember2025-12-31\n0001677940bysi:SEEDTherapeuticsIncMemberbysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember2026-01-012026-03-31\n0001677940bysi:SEEDTherapeuticsIncMemberbysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember2025-01-012025-03-31\n0001677940bysi:SEEDTherapeuticsIncMemberbysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember2020-11-012020-11-30\n0001677940bysi:SEEDTherapeuticsIncMembersrt:MaximumMemberbysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember2020-11-30\n0001677940bysi:JiangsuHengruiPharmaceuticalsCoLtdMemberbysi:DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember2021-09-30\niso4217:CNY\n0001677940bysi:SEEDTherapeuticsIncMemberbysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember2021-09-30\n0001677940bysi:SeedMember2025-01-012025-03-31\n0001677940bysi:SeedMember2025-03-31\n0001677940bysi:SeedMember2026-01-012026-03-31\n0001677940bysi:SeedMember2026-03-31\n0001677940bysi:SeedMember2025-12-31\n0001677940bysi:SeedMembersrt:ScenarioForecastMember2026-12-15\n0001677940bysi:MapfilInvestmentLimitedMemberbysi:SeedMembersrt:ScenarioForecastMember2026-12-152026-12-15\n0001677940bysi:FullTechCorporateDevelopmentLimitedMemberbysi:SeedMembersrt:ScenarioForecastMember2026-12-152026-12-15\n0001677940bysi:WinningViewInvestmentLimitedMemberbysi:SeedMembersrt:ScenarioForecastMember2026-12-152026-12-15\n0001677940bysi:SeedMembersrt:ScenarioForecastMember2026-12-152026-12-15\n0001677940bysi:SeedMembersrt:ScenarioForecastMember2026-06-30\n0001677940bysi:MapfilInvestmentLimitedMemberbysi:SeedMembersrt:ScenarioForecastMember2026-06-302026-06-30\n0001677940bysi:FullTechCorporateDevelopmentLimitedMemberbysi:SeedMembersrt:ScenarioForecastMember2026-06-302026-06-30\n0001677940bysi:WinningViewInvestmentLimitedMemberbysi:SeedMembersrt:ScenarioForecastMember2026-06-302026-06-30\n0001677940bysi:SeedMembersrt:ScenarioForecastMember2026-06-302026-06-30\n0001677940bysi:SeedMember2025-02-192025-02-19\n0001677940bysi:SeedMember2025-02-19\n0001677940bysi:MapfilInvestmentLimitedMemberbysi:SeedMember2025-02-192025-02-19\n0001677940bysi:FullTechCorporateDevelopmentLimitedMemberbysi:SeedMember2025-02-192025-02-19\n0001677940bysi:WinningViewInvestmentLimitedMemberbysi:SeedMember2025-02-192025-02-19\n0001677940bysi:SeedMemberbysi:SeriesA3PreferredStockMemberbysi:SeriesA3FinancingMember2025-09-012025-09-30\n0001677940bysi:SeedMemberbysi:SeriesA3PreferredStockMemberbysi:SeriesA3FinancingMember2024-08-012024-08-31\n0001677940bysi:SeedMember2025-01-012025-01-31\n0001677940bysi:SeedMember2025-01-242025-01-24\n0001677940srt:MaximumMemberbysi:SeedMember2026-03-31\n0001677940srt:MinimumMemberbysi:SeedMember2026-03-31\n0001677940bysi:SEEDLHMGIncMember2026-03-31\n0001677940bysi:SEEDLHIncMember2026-03-31\n0001677940bysi:WanchunHongjiDalianPharmaceuticalsLtdMember2026-03-31\n0001677940bysi:SeedTherapeuticsUSIncMember2026-03-31\n0001677940bysi:SEEDTechnologyLimitedMember2026-03-31\n0001677940bysi:SEEDTherapeuticsIncMember2026-03-31\n0001677940bysi:BeijingWanchunPharmaceuticalTechnologyLtdMember2026-03-31\n0001677940bysi:DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember2026-03-31\n0001677940bysi:WanchunBiotechnologyDalianLtdMember2026-03-31\n0001677940bysi:WanchunBiotechnologyLimitedMember2026-03-31\n0001677940bysi:BeyondSpringHKMember2026-03-31\n0001677940bysi:BeyondSpringLtdMember2026-03-31\n0001677940bysi:BeyondSpringPharmaceuticalsIncMember2026-03-31\n0001677940bysi:SeedMember2026-03-31\n0001677940bysi:SEEDTherapeuticsIncMember2025-01-31\n00016779402025-03-31\n00016779402024-12-31\n0001677940us-gaap:ParentMember2026-01-012026-03-31\n0001677940us-gaap:ParentMember2025-01-012025-03-31\n0001677940us-gaap:NoncontrollingInterestMember2026-03-31\n0001677940us-gaap:ParentMember2026-03-31\n0001677940us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-31\n0001677940us-gaap:RetainedEarningsMember2026-03-31\n0001677940us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001677940us-gaap:CommonStockMember2026-03-31\n0001677940us-gaap:NoncontrollingInterestMember2026-01-012026-03-31\n0001677940us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-31\n0001677940us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001677940us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001677940us-gaap:CommonStockMember2026-01-012026-03-31\n0001677940us-gaap:NoncontrollingInterestMember2025-12-31\n0001677940us-gaap:ParentMember2025-12-31\n0001677940us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-31\n0001677940us-gaap:RetainedEarningsMember2025-12-31\n0001677940us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001677940us-gaap:CommonStockMember2025-12-31\n0001677940us-gaap:NoncontrollingInterestMember2025-03-31\n0001677940us-gaap:ParentMember2025-03-31\n0001677940us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-31\n0001677940us-gaap:RetainedEarningsMember2025-03-31\n0001677940us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001677940us-gaap:CommonStockMember2025-03-31\n0001677940us-gaap:NoncontrollingInterestMember2025-01-012025-03-31\n0001677940us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31\n0001677940us-gaap:RetainedEarningsMember2025-01-012025-03-31\n0001677940us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001677940us-gaap:CommonStockMember2025-01-012025-03-31\n0001677940us-gaap:NoncontrollingInterestMember2024-12-31\n0001677940us-gaap:ParentMember2024-12-31\n0001677940us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31\n0001677940us-gaap:RetainedEarningsMember2024-12-31\n0001677940us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001677940us-gaap:CommonStockMember2024-12-31\n0001677940us-gaap:SegmentDiscontinuedOperationsMember2026-01-012026-03-31\n0001677940us-gaap:SegmentDiscontinuedOperationsMember2025-01-012025-03-31\n00016779402026-04-30\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\nWashington, D.C. 20549\n\n \n\n \n\n**FORM** **10-Q**\n\n \n\n \n\n(Mark One)\n\n \n\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n**For the quarterly period ended March 31, 2026**\n\n \n\nor\n\n \n\n☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from            to\n\n \n\nCommission file number: **001-38024**\n\n \n\n \n\n**BeyondSpring Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n \n\n**Cayman Islands**\n\n**Not Applicable**\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n \n\n**100 Campus Drive, West Side, 4th Floor, Suite 410**\n\n**Florham Park, New Jersey**\n\n**07932**\n\n(Address of Principal Executive Offices)\n\n(Zip Code)\n\n \n \n\n**(646) 305-6387**\n\n(Registrant’s telephone number, including area code)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n\n \n\n**Trading Symbol(s)**\n\n \n\n**Name of each exchange on which registered**\n\n**Ordinary Shares, par value $0.0001 per share**\n\n \n\n**BYSI**\n\n \n\n**The Nasdaq Stock Market LLC**\n\n \n\n \n\n \n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n \n\nEmerging growth company\n\n☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs of April 30, 2026, 41,119,820 shares of the Registrant’s ordinary shares, par value $0.0001 per share, were outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n \n\n**BEYONDSPRING INC.**\n\n**FORM** **10-Q FOR THE QUARTER ENDED MARCH** **31, 2025**\n\n**TABLE OF CONTENTS**\n\n \n\n \n\n**Page**\n\n \n\n[FORWARD-LOOKING STATEMENTS](#fwd)\n\n[1](#fwd)\n\n \n \n\n[PART I.](#p1)\n\n[FINANCIAL INFORMATION](#p1)\n\n[3](#p1)\n\n \n \n \n\n[Item 1.](#p1i1)\n\n[Financial Statements](#p1i1)\n\n[3](#p1i1)\n\n \n[Condensed Consolidated Balance Sheets](#bs)\n[3](#bs)\n\n \n[Condensed Consolidated Statements of Comprehensive Income (Loss)](#ci)\n[4](#ci)\n\n \n[Condensed Consolidated Statements of Shareholders’ Deficit](#sd)\n[5](#sd)\n\n \n[Condensed Consolidated Statements of Cash Flows](#cf)\n[6](#cf)\n\n \n[Notes to Condensed Consolidated Financial Statements](#notes)\n[7](#notes)\n\n[Item 2.](#p1i2)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#p1i2)\n\n[17](#p1i2)\n\n[Item 3.](#p1i3)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#p1i3)\n\n[28](#p1i3)\n\n[Item 4.](#p1i4)\n\n[Controls and Procedures](#p1i4)\n\n[28](#p1i4)\n\n \n \n \n\n[PART II.](#p2)\n\n[OTHER INFORMATION](#p2)\n\n[29](#p2)\n\n \n \n \n\n[Item 1.](#p2i1)\n\n[Legal Proceedings](#p2i1)\n\n[29](#p2i1)\n\n[Item 1A.](#p2i1a)\n\n[Risk Factors](#p2i1a)\n\n[29](#p2i1a)\n\n[Item 2.](#p2i2)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities](#p2i2)\n\n[29](#p2i2)\n\n[Item 3.](#p2i3)\n\n[Defaults Upon Senior Securities](#p2i3)\n\n[29](#p2i3)\n\n[Item 4.](#p2i4)\n\n[Mine Safety Disclosures](#p2i4)\n\n[29](#p2i4)\n\n[Item 5.](#p2i5)\n\n[Other Information](#p2i5)\n\n[29](#p2i5)\n\n[Item 6.](#p2i6)\n\n[Exhibits](#p2i6)\n\n[30](#p2i6)\n\n \n \n \n\n[SIGNATURES](#sign)\n[31](#sign)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n \n\n**FORWARD-LOOKING STATEMENTS**\n\n \n\nThis Quarterly Report on Form 10-Q contains forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements stated in or implied by these forward-looking statements.\n\n \n\nAll statements other than statements of historical facts are forward-looking statements. These forward-looking statements are made under the “safe harbor” provision under Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and as defined in the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. You should refer to “Part II. Other Information—Item 1A. Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and other documents we file with the Securities and Exchange Commission (the “SEC”) for specific risks that could cause actual results to be significantly different from those stated in or implied by these forward-looking statements. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from any future results stated in or implied by these forward-looking statements.\n\n \n\nForward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:\n\n \n\n \n\n●\n\nthe initiation, timing, progress and results of our studies in animals and clinical trials, and our research and development programs;\n\n \n\n \n\n●\n\nour ability to advance our product candidates into, and successfully complete, clinical trials;\n\n \n\n \n\n●\n\nour reliance on the success of our clinical-stage product candidates;\n\n \n\n \n\n●\n\nthe timing or likelihood of regulatory filings and approvals;\n\n \n\n \n\n●\n\nour ability to address the concerns identified in the Complete Response Letter issued by the Food and Drug Administration, or FDA, in November 2021 regarding the New Drug Application, or NDA, seeking approval of Plinabulin in combination with granulocyte colony-stimulating factor, for the prevention of chemotherapy-induced neutropenia, or CIN;\n\n \n\n \n\n●\n\nour ability to file the NDA submission for the non-small cell lung cancer, or NSCLC, indication with the National Medical Products Administration, or NMPA, in China;\n\n \n\n \n\n●\n\nthe commercialization of our product candidates, if approved;\n\n \n\n \n\n●\n\nour ability to develop sales and marketing capabilities;\n\n \n\n \n\n●\n\nthe pricing and reimbursement of our product candidates, if approved;\n\n \n\n \n\n●\n\nthe implementation of our business model, strategic plans for our business and technology;\n\n \n\n \n\n●\n\nthe scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;\n\n \n\n \n\n \n\n1\n\n \n\n \n\n \n\n●\n\nour ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties;\n\n \n\n \n\n●\n\ncosts associated with defending intellectual property infringement, product liability and other claims;\n\n \n\n \n\n●\n\nregulatory development in the U.S., China and other jurisdictions;\n\n \n\n \n\n●\n\nestimates of our expenses, future revenues, capital requirements and our needs for additional financing;\n\n \n\n \n\n●\n\nthe potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;\n\n \n\n \n\n●\n\nour ability to maintain and establish collaborations or obtain additional grant funding;\n\n \n\n \n\n●\n\nthe rate and degree of market acceptance of our product candidates;\n\n \n\n \n\n●\n\ndevelopments relating to our competitors and our industry, including competing therapies;\n\n \n\n \n\n●\n\nour ability to effectively manage our anticipated growth;\n\n \n\n \n\n●\n\nour ability to attract and retain qualified employees and key personnel;\n\n \n\n \n\n●\n\nour future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance;\n\n \n\n \n\n●\n\nthe future trading price of our ordinary shares and impact of securities analysts’ reports on these prices;\n\n \n\n \n\n●\n\nour ability to meet Nasdaq’s continued listing requirements;\n\n \n\n \n\n●\n\nthe impact of widespread health developments, and the responses thereto, which could materially and adversely affect, among other things, enrollment of patients in our clinical trials, timing and completion of regulatory or other required inspections, our expected timeline for data readouts of our clinical trials and certain regulatory filings for our product candidates, and the review and approval timeline of regulatory authorities; and\n\n \n\n \n\n●\n\nother risks and uncertainties, including those listed under “Part II. Other Information—Item 1A. Risk Factors.”\n\n \n\nThe items in “Part II. Other Information—Item 1A. Risk Factors” of this Quarterly Report on Form 10-Q reference the principal contingencies and uncertainties to which we believe we are subject, which should be considered in evaluating any forward-looking statements contained in this Quarterly Report on Form 10-Q.\n\n \n\nThe forward-looking statements in this Quarterly Report on Form 10-Q speak only to our views as of the date of this Quarterly Report on Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.\n\n \n\nThis Quarterly Report on Form 10-Q contains market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information included in this Quarterly Report on Form 10-Q is generally reliable, such information is inherently imprecise.\n\n \n\n2\n\n \n\n \n\n \n\n**PART I.**\n\n**FINANCIAL INFORMATION**"}